Safety of selamectin in dogs.
Selamectin is a broad-spectrum avermectin endectocide for treatment and control of canine parasites. The objective of these studies was to evaluate the clinical safety of selamectin for topical use in dogs 6 weeks of age and older, including breeding animals, avermectin-sensitive Collies, and heartworm-positive animals. The margin of safety was evaluated in Beagles, which were 6 weeks old at study initiation. Reproductive, heartworm-positive, and oral safety studies were conducted in mature Beagles. Safety in Collies was evaluated in avermectin-sensitive, adult rough-coated Collies. Studies were designed to measure the safety of selamectin at the recommended dosage range of 6-12mgkg(-1) of body weight. Endpoints included clinical examinations, clinical pathology, gross and microscopic pathology, and reproductive indices. Selected variables in the margin of safety and reproductive safety studies were subjected to statistical analyses. Pups received large doses of selamectin at the beginning of the margin of safety study when they were 6 weeks of age and at their lowest body weight, yet displayed no clinical or pathologic evidence of toxicosis. Similarly, selamectin had no adverse effects on reproduction in adult male and female dogs. There were no adverse effects in avermectin-sensitive Collies or in heartworm-positive dogs. Oral administration of the topical formulation caused no adverse effects. Selamectin is safe for topical use on dogs at the recommended minimum dosage of 6mgkg(-1) (6-12mgkg(-1)) monthly starting at 6 weeks of age, and including dogs of reproducing age, avermectin-sensitive Collies, and heartworm-positive dogs.
Animal Health Clinical Affairs, Pfizer Central Research, Groton, CT 06340, USA. mark_j_novotny@groton.pfizer.com
M J
MJ
Novotny
M J
MJ
Krautmann
J C
JC
Ehrhart
C S
CS
Godin
E I
EI
Evans
J W
JW
McCall
F
F
Sun
T G
TG
Rowan
A D
AD
Jernigan
D000284:Administration, Oral; D000287:Administration, Topical; D000818:Animals; D000871:Anthelmintics / Q000009:adverse effects / Q000627:therapeutic use*; D000977:Antiparasitic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004184:Dirofilariasis / Q000188:drug therapy*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004478:Ectoparasitic Infestations / Q000188:drug therapy / Q000662:veterinary*; D005260:Female; D005333:Fetus / Q000187:drug effects; D007559:Ivermectin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D011247:Pregnancy; D012098:Reproduction / Q000187:drug effects
D000871:Anthelmintics; D000977:Antiparasitic Agents; D007559:Ivermectin; C019264:avermectin; C414354:selamectin